Overview

Efficacy of Pyrotinib Plus Capecitabine in HER2-positive MBC With Active Brain Metastases That Have Failed ADCs

Status:
NOT_YET_RECRUITING

Trial end date:
2027-01-31

Target enrollment:

Participant gender:

Summary

To evaluate the efficacy and safety of pyrotinib plus capecitabine in HER2-positive breast cancer patients with active brain metastases that have failed ADCs

Phase:

PHASE2

Details

Lead Sponsor:

Henan Cancer Hospital

Treatments:

Capecitabine
pyrotinib